Shanghai Pharmaceuticals Holding Co Ltd Class H
02607: XHKG (HKG)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
HK$13.10 | Psfwsy | Lpqrvxkf |
Shanghai Pharmaceuticals Is the Second-Largest Medical Distributor in China
Business Strategy and Outlook
Shanghai Pharmaceuticals’, or SPH’s, revenue grew at a compounded annual growth rate of 10.9% in the past 10 years. The growth is driven by its medical distribution segment due to industry consolidation and expansion. Similar to other larger pharmaceutical distributors, SPH, in our view, is likely to grow faster than the distribution industry average in the next three years as the industry further consolidates.